ClinicalTrials.gg
CompletedNCT03345979Updated Aug 11, 2020Results posted

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

A Phase 3 interventional study of Aripiprazole Lauroxil and Paliperidone Palmitate in Schizophrenia, sponsored by Alkermes, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing aripiprazole lauroxil in Schizophrenia — none open to participants now, none under way, none of them phase 3. aripiprazole lauroxil · Schizophrenia.

Enrollment
4th of 10
200 · median 114
Started
2017
the only one that year
Phase 3
4 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
8 of 10
Alkermes, Inc.

Among the 10 studies testing aripiprazole lauroxil in Schizophrenia, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 8th registered.

Schizophrenia

3,567 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 10 studies testing aripiprazole lauroxil in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About aripiprazole lauroxil

aripiprazole lauroxil: first FDA approval 2015 (ARISTADA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole lauroxil in Schizophrenia as a file.
02

Study summary

This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Alkermes
  • schizophrenia
  • aripiprazole lauroxil
  • ARISTADA
  • ARISTADA INITIO
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of schizophrenia
  • Requires acute treatment for symptoms of schizophrenia
  • Willing and able to be confined to an inpatient study unit for up to 3-4 weeks
  • Has experienced at least one previous hospitalization for schizophrenia
  • Has been able to achieve outpatient status for more than 3 months in the past year
  • Has a (BMI) between 18.0 and 40.0 kg/m\^2
  • Resides in a stable living situation when not hospitalized
  • Has an identified reliable caregiver (for example, family member)
  • Additional criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Poses a current suicide risk
  • Pregnant, planning to become pregnant, or breastfeeding
  • Initiated first antipsychotic treatment within the past 12 months
  • Has received a long-acting injectable antipsychotic in the past 3 months
  • Has participated in a clinical study involving any product within the past 3 months, or is currently participating in a clinical study involving an investigational product.
  • A positive urine drug test for drugs of abuse
  • Additional criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Treatment Group 1

    Regular injections

    Combination Product: Aripiprazole Lauroxil

  • Active comparator
    Treatment Group 2

    Regular injections

    Drug: Paliperidone Palmitate

Interventions

  • Combination productAripiprazole Lauroxil

    Intramuscular injection; study drug provided using a pre-filled syringe

    Also known as: ARISTADA, ARISTADA INITIO

  • Intramuscular injection

    Also known as: Invega Sustenna

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4

    Change within treatment groups of Positive and Negative Syndrome Scale (PANSS) total score between baseline and week 4 based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.

    Time frame: Baseline and 4 weeks

Secondary outcomes

  1. Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4

    Least squares mean change in Positive and Negative Syndrome Scale (PANSS) between at 4 weeks from Mixed Models Repeated Measures (MMRM). The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

    Time frame: Baseline and 4 weeks

  2. Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9

    Change within treatment groups from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.

    Time frame: Baseline and 9 weeks

  3. Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25

    Change within treatment groups at baseline Positive and Negative Syndrome Scale (PANSS) and at 25 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

    Time frame: Baseline and 25 weeks

  4. Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9

    Least squares mean change from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks from Mixed Models Repeated Measures (MMRM).The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

    Time frame: Baseline and 9 weeks

  5. Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25

    Least squares mean change in Positive and Negative Syndrome Scale (PANSS) total score at week 25 from Mixed Models Repeated Measures. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

    Time frame: Baseline and 25 weeks

  6. Number of Participants With Serious and Non-serious Adverse Events (AEs)

    Time frame: Up to 25 weeks

07

Results

Posted Aug 11, 2020

Participant flow

Participant flow — Overall Study
MilestoneAripiprazole LauroxilPaliperidone Palmitate
Started99101
Completed5643
Not completed4358
Withdrew: Withdrawal by subject2031
Withdrew: Adverse event1011
Withdrew: Lost to follow-up89
Withdrew: Lack of efficacy42
Withdrew: Protocol violation13
Withdrew: Physician decision02

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4

Change within treatment groups of Positive and Negative Syndrome Scale (PANSS) total score between baseline and week 4 based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
units on a scaleAripiprazole LauroxilPaliperidone Palmitate
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4-17.4 ± 11.57-20.1 ± 13.72
Statistical analysis
  • Aripiprazole Lauroxil · t-test, 2 sided · p = <.001
  • Paliperidone Palmitate · t-test, 2 sided · p = <.001
SecondaryLeast Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4

Least squares mean change in Positive and Negative Syndrome Scale (PANSS) between at 4 weeks from Mixed Models Repeated Measures (MMRM). The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

Time frame:
Baseline and 4 weeks
Reported as:
Least squares mean · units on a scale
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
units on a scaleAripiprazole LauroxilPaliperidone Palmitate
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4-17.3 ± 1.28-19.3 ± 1.25
SecondaryChange in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9

Change within treatment groups from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.

Time frame:
Baseline and 9 weeks
Reported as:
Mean · units on a scale
Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9
units on a scaleAripiprazole LauroxilPaliperidone Palmitate
Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9-19.8 ± 11.61-22.5 ± 13.98
SecondaryChange in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25

Change within treatment groups at baseline Positive and Negative Syndrome Scale (PANSS) and at 25 weeks based on the observed data without imputation for missing data. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

Time frame:
Baseline and 25 weeks
Reported as:
Mean · units on a scale
Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25
units on a scaleAripiprazole LauroxilPaliperidone Palmitate
Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25-23.3 ± 11.25-21.7 ± 14.37
SecondaryLeast Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9

Least squares mean change from baseline Positive and Negative Syndrome Scale (PANSS) and 9 weeks from Mixed Models Repeated Measures (MMRM).The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

Time frame:
Baseline and 9 weeks
Reported as:
Least squares mean · units on a scale
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9
units on a scaleAripiprazole LauroxilPaliperidone Palmitate
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 9-18.8 ± 1.33-21.5 ± 1.34
SecondaryLeast Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25

Least squares mean change in Positive and Negative Syndrome Scale (PANSS) total score at week 25 from Mixed Models Repeated Measures. The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition

Time frame:
Baseline and 25 weeks
Reported as:
Least squares mean · units on a scale
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25
units on a scaleAripiprazole LauroxilPaliperidone Palmitate
Least Squares Mean Change in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 25-22.0 ± 1.42-21.1 ± 1.53
SecondaryNumber of Participants With Serious and Non-serious Adverse Events (AEs)
Time frame:
Up to 25 weeks
Reported as:
Count of participants · Participants
Number of Participants With Serious and Non-serious Adverse Events (AEs)
ParticipantsAripiprazole LauroxilPaliperidone Palmitate
Number of Participants With Serious and Non-serious Adverse Events (AEs)6972

Adverse events

Collected over Adverse event data was collected over 25 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole Lauroxil0/99 (0%)8/99 (8.1%)39/99 (39.4%)
Paliperidone Palmitate0/101 (0%)7/101 (6.9%)50/101 (49.5%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventAripiprazole LauroxilPaliperidone Palmitate
SchizophreniaPsychiatric disorders5/992/101
Psychotic disorderPsychiatric disorders2/990/101
LeukocytosisBlood and lymphatic system disorders1/990/101
HypercalcaemiaMetabolism and nutrition disorders1/990/101
Generalised tonic-clonic seizureNervous system disorders1/990/101
Suicide attemptPsychiatric disorders1/991/101
Suicidal ideationPsychiatric disorders1/990/101
Renal failureRenal and urinary disorders1/990/101
Alcohol poisoningInjury, poisoning and procedural complications0/991/101
OverdoseInjury, poisoning and procedural complications0/991/101
Most frequent other events
Most frequent other events
EventAripiprazole LauroxilPaliperidone Palmitate
Injection Site PainGeneral disorders17/9925/101
Weight increasedInvestigations9/9917/101
AkathisiaNervous system disorders9/9911/101
HeadacheNervous system disorders8/998/101
SomnolenceNervous system disorders4/997/101
DystoniaNervous system disorders3/996/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aripiprazole LauroxilPaliperidone PalmitateTotal
Mean43.5 ± 9.6743.4 ± 10.8343.4 ± 10.25
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole LauroxilPaliperidone PalmitateTotal
Female262551
Male7376149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aripiprazole LauroxilPaliperidone PalmitateTotal
Hispanic or Latino81119
Not Hispanic or Latino9190181
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aripiprazole LauroxilPaliperidone PalmitateTotal
American Indian or Alaska Native000
Asian246
Native Hawaiian or Other Pacific Islander000
Black or African American7278150
White251742
More than one race022
Unknown or Not Reported000
Positive and Negative Syndrome Scale (PANSS) Total Score
Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale)Aripiprazole LauroxilPaliperidone PalmitateTotal
Mean94.1 ± 9.0494.6 ± 8.4194.4 ± 8.71
08

Study locations

16 sites
  • Alkermes Investigational Site
    Little Rock, Arkansas 72211, United States
  • Alkermes Investigational Site
    Rogers, Arkansas 72758, United States
  • Alkermes Investigational Site
    Cerritos, California 90703, United States
  • Alkermes Investigational Site
    Culver City, California 90230, United States
  • Alkermes Investigational Site
    Garden Grove, California 92845, United States
  • Alkermes Investigational Site
    Lemon Grove, California 91945, United States
  • Alkermes Investigational Site
    Hialeah, Florida 33012, United States
  • Alkermes Investigational Site
    Chicago, Illinois 60640, United States
  • Alkermes Investigational Site
    Hoffman Estates, Illinois 60169, United States
  • Alkermes Investigational Site
    Flowood, Mississippi 39232, United States
  • Alkermes Investigational Site
    Saint Louis, Missouri 63141, United States
  • Alkermes Investigational Site
    Las Vegas, Nevada 89102, United States
  • Alkermes Investigational Site
    Berlin, New Jersey 08009, United States
  • Alkermes Investigational Site
    Austin, Texas 78754, United States
  • Alkermes Investigational Site
    Garland, Texas 75042, United States
  • Alkermes Investigational Site
    Richardson, Texas 75080, United States
09

References and documents

Publications

  • Nasrallah HA, Weiden PJ, Walling DP, Du Y, Yao B, Yagoda S, Claxton A. Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC Psychiatry. 2021 Oct 8;21(1):492. doi: 10.1186/s12888-021-03420-x. PubMed 34625041 ↗
  • Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, Yagoda S, Bidollari I, Keane E, Cash E. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. J Clin Psychiatry. 2020 May 19;81(3):19m13207. doi: 10.4088/JCP.19m13207. PubMed 32433835 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2019, 15 months.

Results were first posted in Aug 2020, 1 year 4 months after primary completion. A results delay was requested in Apr 2020.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 15 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 17, 2017
StartActual
Nov 15, 2017
Primary completionActual
Mar 12, 2019
CompletionActual
Mar 12, 2019
Results delay requested
Apr 23, 2020
Results first posted
Aug 11, 2020
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03345979
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 15, 2017
Primary completion
Mar 12, 2019
Completion
Mar 12, 2019
Results posted
Aug 11, 2020
Last update
Aug 11, 2020

Study contacts

Sanjeev Pathak, MD
study director · Alkermes, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole lauroxil

Start the discussion